��ժҪ��Ϣ

[an error occurred while processing this directive]

��Ƥ��Բ�ѧ��־ 2002, 28(1) 10-13 DOI: ISSN: 2096-5540 CN: 32-1880/R

��Ŀ¼ | ��Ŀ¼ | �� | �߼�� [��ӡ��ҳ] [�ر�]

��

	��չ��

	��Ϣ
	Supporting info
	PDFȫ��
	[HTMLȫ��]
	�ο��
	��뷴��
	�ѱ��Ƽ��
	��ҵ��
	��ù��
	��ñ��
	Email Alert
	��·��
	��Ϣ
	��Ĺؼ��
	ҩ��
	��
	��
	��
	��ǿ
	��Ԫ��
	��¡��
	PubMed
	Article by
	Article by
	Article by
	Article by

��ҩ��о��չ

��, ��ǿ, ��Ԫ��, ��¡��

�й�ҽѧ��ѧԺ��й�Э��ҽ�ƴ�ѧƤ��о�� Ͼ� 210042

ժҪ��

��ѧ�߸��γɻ��ƿ��һЩҩ��.��Щҩ��ά��ԭ�ϳɺͷ��ڼ��ӵ��,�ڿ��ʺ��ۺ��۸��γɷ��нϺõ�Ӧ��ǰ��Ǳ��.

�ؼ���� ҩ��

Abstract:

Keywords:

�ո�� 2001-05-16 �޻�� ��淢��

DOI:

��Ŀ:

ͨѶ��:

��߼��:

�ο��ף�

[1] Berman B, Duncan MR. Pentoxifylline inhibits the proliferation of human fibroblasts derived from keloid, scleroderma and morphoea skin and their production of collagen, glycosaminoglycans and fibronectin. Br J Dermatol, 1990,123(3): 339-346.
[2] Berman B, Wietzerbin J, Sanceau J, et al. Pentoxifylline inhibits certain constitutive and tumor necrosis factor-alpha-induced activities of human normal dermal fibroblasts. J Invest Dermatol, 1992,98 (5): 706-712.
[3] Dans MJ, Isseroff R. Inhibition of collagen lattice contraction by pentoxifylline and interferon-alpha, -beta, and -gamma. J Invest Dermatol, 1994,102 (1): 118-121.
[4] Duncan MR, Hasan A, Berman B. Pentoxifylline, pentifylline, and interferons decrease type �� and �� procollagen mRNA levels in dermal fibroblasts: evidence for mediation by nuclear factor 1 down-regulation. J Invest Dermatol, 1995,104(2): 282-286.
[5] Wong TW, Lee JY, Sheu HM, et al. Relief of pain and itch associated with keloids on treatment with oxpentifylline. Br J Dermatol, 1999, 140(4): 771-772.
[6] Hu D, Hughes MA, Cherry GW. Topical tamoxifen--a potential therapeutic regime in treating excessive dermal scarring? Br J Plast Surg, 1998,51(6): 462-469.
[7] Hashimoto M, Inoue S, Ogawa S, et al. Rapid fragmentation of vimentin in human skin fibroblasts exposed to tamoxifen: a possible involvement of caspase-3. Biochem Biophys Res Commun, 1998,247(2): 401-406.
[8] Chau D, Mancoll JS, Lee S, et al. Tamoxifen downregulates TGF-beta production in keloid fibroblasts. Ann Plast Surg, 1998,40(5):490-493.
[9] Suzawa H, Kikuchi S, Arai N, et al. The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. Jpn J Pharmacol, 1992,60(2): 91-96.
[10] Yamada H, Tajima S, Nishikawa T, et al. Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts. J Biochem (Tokyo), 1994,116(4): 892-897.
[11] Shigeki S, Murakami T, Yata N, et al. Treatment of keloid and hypertrophic scars by iontophoretic transdermal delivery of traanilast. Scand J Plast Reconstr Surg Hand Surg, 1997,31 (2): 151-158.
[12] Murakami T, Yoshioka M, Yumoto R, et al. Topical delivery of keloid therapeutic drug, tranilast, by combined use of oleic acid and propylene glycol as a penetration enhancer: evaluation by skin microdialysis in rats.J Pharm Pharmacol, 1998,50(1): 49-54.
[13] Murad S, Walker LC, Tajima S, et al. Minimum structural requirements for minoxidil inhibition of lysyl hydroxylase in cultuued fibroblasts. Arch Biochem Biophys, 1994,308 (1): 42-47.
[14] Parish JL, Hughes MA, Cherry GW, et al. The effect of minoxidil analogues and metabolltes on the contraction of collagen latices by human skin fibroblasts. Br J Plast Surg, 1995,48(3): 154-160.
[15] Priestley GC, Aldridge RD, Sime PJ, et al. Skin fibroblast activity in pretibial myxoedema and the effect of octreotide (Sandostatin) in vitro. Br J Dermatol, 1994,131(1): 52-56.
[16] Kaneko M, Inoue H, Nakazawa R,et al. Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts. Clin Exp Immunol, 1998,113 (1): 72-76.
[17] Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fiibrosis at the translational level. Am J Physiol, 1999,276(2 Pt 1): L311-318.
[18] Shetlar MR, Shetlar DJ, Bloom RF, et al. Involution of keloid imoplants in athymic mice treated with pirfenidone or with triamcinolone. J Lab Clin Med, 1998,132(6): 491-496.
[19] Dolynchuk KN, Ziesmann M, Serletti JM. Topical putrescine (Fibrostat)in treatment of hypertrophic scars: phase �� study. Plast Reconstr Surg,1996,97(1): 117-123.
[20] Shigematsu T, Tajima S, Nishikawa T, et al. Inhibition of collagen hydroxylation by lithospermic acid magnesium salt, a novel compound isolated from Salviac miltiorrhizae Radix. Biochim Biophys Acta, 1994, 1200(1):79-83.
[21] Yamada H, Shigematsu T, Tajima S, et al. Screening of potent inhibitors of collagen synthesis in cultured human skin fibroblasts. Arch Dermatol Res, 1995,287(5): 506-508.
[22] Baum TM, Busuito MJ. Use of a glycerin-based gel sheeting in scar management. Adv Wound Care, 1998,11 (1): 40-43.
[23] Phillips TJ, Gerstein AD, Lordan V. A randomized controlled trial of hydrocolloid dressing in the treatment of hypertrophic scars and keloids. Dermatol Surg, 1996,22 (9): 775-778.
[24] Takeuchi M, Tredget EE, Scott PG, et al. The antifibrogenic effects of liposome-encapsulated IFN-alpha2b cream on skin wounds. J Interferon Cytokine Res, 1999,19(12): 1413-1419.
[25] Wang X, Smith P, Pu LL,et al. Exogenous transforming growth factor beta(2) modulates collagen �� and collagen �� synthesis in proliferative scar xenografts in nude rats. J Surg Res, 1999,87(2): 194-200.
[26] Kitzis V, Engrav LiH, Quinn LS. Transient exposure to tumor necrosis factor-alpha inhibits collagen accumulation by cultured hypertrophic scar fibroblasts. J Surg Res, 1999,87(1): 134-141.

��е��

1��ǿ,�̲�.��ش�ë��о��չ[J]. ��Ƥ��Բ�ѧ��־, 2007,33(4): 244-

2��¼�,��ѧ˼,��,Ⱥ.ҩ��Ժ�Ƥ��[J]. ��Ƥ��Բ�ѧ��־, 2006,32(1): 10-

3��,�Ÿ��,��.��Ǿֲ�ҩ��ƽ�չ[J]. ��Ƥ��Բ�ѧ��־, 2006,32(2): 108-

4��Ǯ��,��ǧ��,�Ź��.��͡��ҩ��Ƥ��Ƶ�Ӧ��չ��[J]. ��Ƥ��Բ�ѧ��־, 2006,32(3): 139-

5��һƽ,��.��鰷ҩ��Ƥ��ʪ��༲��е�Ӧ��[J]. ��Ƥ��Բ�ѧ��־, 2008,34(5): 293-295

6��,֣��.��о��չ[J]. ��Ƥ��Բ�ѧ��־, 2009,35(2): 87-89

7�� ȫ��.Ƥ��ƺ�ҩ��Ƶ��°е�[J]. ��Ƥ��Բ�ѧ��־, 2009,35(3): 170-172

8��³�� ֣��.ҩ��յ��Ժ��Ǵ�[J]. ��Ƥ��Բ�ѧ��־, 2009,35(5): 294-296

9�� ǧ��.��ͷ��ɺ�ͷ�߿��ҩ��״��ҩ��о��չ[J]. ��Ƥ��Բ�ѧ��־, 2009,35(6): 399-401

10�� ƻ�.��۵��ҩ��[J]. ��Ƥ��Բ�ѧ��־, 2010,36(3): 178-180

11�� ɣ�� ͨ ��ѩ�� ߷�.ҩ�ﳬ��ۺ��Ƽ��ܽ��ۺ��һ��[J]. ��Ƥ��Բ�ѧ��־, 2011,37(6): 335-336